TLPH Stock Overview A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Talphera, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Talphera Historical stock prices Current Share Price US$0.64 52 Week High US$1.61 52 Week Low US$0.60 Beta 0.23 1 Month Change -8.60% 3 Month Change -29.92% 1 Year Change -19.16% 3 Year Change -94.31% 5 Year Change -98.58% Change since IPO -99.30%
Recent News & Updates
Talphera Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Dec 12
Talphera Receives a Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Nov 30
Talphera, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Talphera, Inc. Announces Management Changes Aug 15
Talphera, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 06
Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024 May 16 See more updates
Talphera Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Dec 12
Talphera Receives a Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Nov 30
Talphera, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Talphera, Inc. Announces Management Changes Aug 15
Talphera, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 06
Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024 May 16
Talphera, Inc. to Report Q1, 2024 Results on May 14, 2024 May 03
Talphera, Inc., Annual General Meeting, Jun 24, 2024 Apr 21
Talphera, Inc. to Report Q4, 2023 Results on Mar 06, 2024 Feb 27
New major risk - Share price stability Jan 31
Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director Jan 23
Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index Jan 10
Talphera Expects to Initiate the Registrational Study of Niyad Jan 09
New major risk - Financial position Nov 20
Consensus EPS estimates upgraded to US$1.16 loss, revenue downgraded Nov 15
AcelRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 27
AcelRx Pharmaceuticals Receives Non-Compliance Notice From Nasdaq Oct 21
AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study Oct 05
AcelRx Pharmaceuticals, Inc., Annual General Meeting, Oct 10, 2023 Aug 29
New major risk - Share price stability Aug 22
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 12
AcelRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 29
New major risk - Shareholder dilution Jul 24
Acelrx Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule Jun 17
First quarter 2023 earnings released: EPS: US$0.006 (vs US$1.19 loss in 1Q 2022) May 11
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 02
Consensus forecasts updated Nov 21
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16
Price target decreased to US$4.00 Nov 16
AcelRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 04
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 Nov 01 AcelRx Pharmaceuticals Announces Reverse Stock Split to Regain Compliance
Consensus forecasts updated Aug 26
Consensus forecasts updated Aug 18
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well Aug 18
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 12 AcelRx Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC Aug 05
Nasdaq Grants Additional time to AcelRx Pharmaceuticals to Regain Compliance Jul 30
AcelRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 29
AcelRx Pharmaceuticals: Finally, Plan B Jun 06 AcelRx Pharmaceuticals Receives Non-Compliance Notice from Nasdaq
Consensus revenue estimates fall by 16% May 23
AcelRx Pharmaceuticals, Inc. Provides Update on Reduced FDA REMS Requirements Related to DSUVIA May 20
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint May 17
Acelrx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (Sst) Compared to Standard Intravenous Opioids During Plastic Surgery Procedures Performed Under General Anesthesia May 12 AcelRx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022
Price target decreased to US$4.00 Apr 27
AcelRx Pharmaceuticals, Inc. Announces Summary of Results from Podium Presentation on DSUVIA, at the Aesthetic Meeting 2022 Apr 26
AcelRx Pharmaceuticals, Inc. Announces Publication of A Study Evaluating the Use of A Sufentanil Sublingual Tablet 30 Mcg for Management of Pain of Radiofrequency Microneedling of the Face or Abdomen Apr 01
AcelRx Pharmaceuticals, Inc. Announces the Publication of Comparative Data Between Two Different Dialysis Circuit Anticoagulants in Pediatric Patients Undergoing Continuous Renal Replacement Therapy Mar 30
Consensus forecasts updated Mar 17
AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers Mar 16
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 12
AcelRx Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
AcelRx Pharmaceuticals, Inc. Announces Resignation of Mark G. Edwards as Board of Director Mar 03
AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet During Awake Plastic Surgery Procedures Feb 02
AcelRx Pharmaceuticals: The Fog Is Getting Thicker Jan 14
AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX) completed the acquisition of Lowell Therapeutics, Inc. Jan 12
AcelRx: Battered And Bruised But Ready For Recovery In 2022 Jan 05
AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery Dec 16
Consensus revenue estimates fall to US$4.66m Dec 03
No longer forecast to breakeven Dec 03
Price target decreased to US$4.25 Dec 02
Third quarter 2021 earnings released: US$0.07 loss per share (vs US$0.10 loss in 3Q 2020) Nov 17
AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck? Oct 02
Second quarter 2021 earnings released: US$0.083 loss per share (vs US$0.082 loss in 2Q 2020) Aug 18
AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm Jul 27 AcelRx Pharmaceuticals, Inc.(NasdaqGM:ACRX) dropped from Russell 3000E Value Index Rosen Law Firm Reminds Purchasers of the Securities of Acelrx Pharmaceuticals, Inc. Between March 17, 2020 and February 12, 2021
FDA agrees with AcelRx to update promotional materials for Dsuvia Jun 17
Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now Jun 11
Pomerantz Law Firm Announces the Filing of A Class Action Against AcelRX Pharmaceuticals, Inc. and Certain Officers Jun 09
AcelRx Pharmaceuticals, Inc. Announces Important Findings from A Podium Presentation on DSUVIA Jun 02
AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles May 31
Consensus revenue estimates fall to US$8.76m May 25
Price target increased to US$6.67 May 23
AcelRx Pharmaceuticals, Inc. Announces an Investigator-Initiated Study of DSUVIA in the Emergency Department for Patients with Sickle Cell Disease May 21
First quarter 2021 earnings released: US$0.079 loss per share (vs US$0.20 loss in 1Q 2020) May 19
AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement May 07
Price target increased to US$6.67 Apr 26
Consensus revenue estimates fall to US$14.5m Mar 23 Shareholder Returns TLPH US Pharmaceuticals US Market 7D -2.3% -1.5% -2.4% 1Y -19.2% 7.9% 23.4%
See full shareholder returns
Return vs Market: TLPH underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is TLPH's price volatile compared to industry and market? TLPH volatility TLPH Average Weekly Movement 15.7% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: TLPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TLPH's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Show more Talphera, Inc. Fundamentals Summary How do Talphera's earnings and revenue compare to its market cap? TLPH fundamental statistics Market cap US$10.82m Earnings (TTM ) -US$15.64m Revenue (TTM ) US$281.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TLPH income statement (TTM ) Revenue US$281.00k Cost of Revenue US$7.16m Gross Profit -US$6.88m Other Expenses US$8.76m Earnings -US$15.64m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.92 Gross Margin -2,449.47% Net Profit Margin -5,565.48% Debt/Equity Ratio 67.7%
How did TLPH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 06:14 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Talphera, Inc. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners David Buck B. Riley Securities, Inc. Andrew D'Silva B. Riley Securities, Inc.
Show 16 more analysts 
